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m’10584 SelectiveReductionofCardiacPainThreeholdinSyndromeX
V. Pasceri, A. Buffon, A.S. Montenero, A. Manzoli, G..Patti, F.Crea,
A. Maseri, G.A. Lanza. Catholic University Rorna, Italy
Previous studias have shown that patients (pts) with syndrome X (SX) have
an increased cardiac sensitivity to painful stimuli. However, it is not clear
whether this finding iacaused by an abnormal pain perception orismerelydue
to an enhanced tendency to repofl chest pain by SX pts, as a consequence
of primaty psychological disorders. We assessed cardiac sensitivity to pain
in 16 SX pts (51 + 6 years, 4 men) and 15 control pts (53 + 8 years, 5
men) undergoing electrophysiologic study, by performing right atrium and
right ventricle pacing with increasing intensity (1 to 10 mA), at a rate 5 beats
higher than patient’s heart rate. To exclude psychologic influence on pain
perception, a false (FP) and a true (TP) pacing were performed in a random
sequence, blinded to both patient and investigator. Nocontrol pts had pacing-
induced pain, while 50% of SX pts reported pain in atrium (P < 0.01) and 94%
in ventricle (P < 0.001). In atrium TP and FP resulted in a similar incidence
of chest pain (50Y0vs 69%, P = 0.37), while in the ventricle TP induced an
higher incidence of pain (94% vs50%, P -=0.05). Pain threshold and severity
were similar during TP and FP in atrium, while in the ventricle pain threshold
was lower and severity higher during TP.
Pein threshold(mA) Pain severity (1-10 scale)
TP FP P TP FP P
Atrium 7.2 & 3.5 6.6 + 3.2 0.42 3,4 * 3.7 3.7 & 3.2 0.87
Ventricle 3.7 l 3.0 7.9 & 2.8 <0.001 7.3 & 2.7 3.1 i 3.5 <0.001
In conclusion, although psychologic factors may influence the report of
cheat pain by SX pt.%a reduced threshold for cardiac pain is detectable in
response to electrical stimulation of right ventricle.
D10585 DiaatolicLeftVentricularFunctionin PatientsWithRefractoryAnginaPectorisAfterLow-Dose
IntermittentUrokinaseTherapy
C.M. Schannwell, F.G.Schoebel, B. Politz, R. Marx, S. Heggen, M. Schmitz,
M. Leschke, B.E. Strauer. C/irricof Carcfio/og~F/eirrricfrffeirre University
Dkseldort Germany
Low-dose intermittent urokinase therapy has been establishedasacombined
rheologic and thrombdytic approach for antiischemic treatment in patients
(pts) with end-stage coronary artery disease and refractory angina pecroris
(AP). The impact of this therapeutic approach on Ieftventricular (LV)diastolic
function as a parameter for myocardial ischamia has not been investigated
so far.
In 25 pts with refractory AP 500000 IU of urokinase were administered
intravenously three times a week a treatment period of 12 weeks (36 in-
jections). Pulsed-wave Doppler echocardiography es an useful tool for the
noninvasive assessment of LV diastolic function was performed and the fol-
lowing Doppler indices were obtained in all pts and 21 normal age-matched
control subjects: peak early diastolic flow velocity (VE); acceleration (AT)and
deceleration timas (DT) of flow velocity in earfy diastole; rates of acceleration
and deceleration of flow velocity in early diastole; peak late diastolic flow
velocity (VA)and isovolumatric relaxation time (IVRT). Pts with refractory AP
had a higher peak A velocity and a prolonged deceleration time. The WA
ratio and the E ares/A area ratio were significantly lower in pts with refractory
AP.After Iow-doae intermittent urokinase therapy diastolic parameters nearly
normalized.
vA [tis] WA ratio VTIENTIA DT [ins] IVRT [ins]
controls 0.48 1.5 2.51 193 82
before UK 0.68” 1.2* 1.87* 262* 117*
after UK 0.57” 1.5” 2.ot” 212- 97-
UK= urokinasetherapy: p c 0.01 vs controls;“p <0.01 vs before UK
Corrc/usion: Diastolic LV function is severly impaired in patients with
refractory AP. Antiischemic effectiveness of low-dose intermittent urokinase
therapy can be verified by improvad diastolic function.
11058-8] ~~~~gct0rsforAn9i09raPhicment0fCoronaf’Y
S.H. Wilson, D.S. Celermajer, A. Naksgomi, R.N. Wyndham, M. Janu,
S.6. Freedman. Depsfimerrts of Cwdio/cW Roya/Prince A/fred Hospita/
and Concord Hospital, Sydney, Australia
Most acute coronary eventa occur as a result of thrombosis at sites of minor
plaque. Therefore, the extent of non-obstructive corona~ artery disease
(CAD), rather than simply the number of savere stenoses, maybe clinically
relevant. We have recently developed and validatad a novel “extent score”
for CAD which measures the percent of the corona~ tree involved by non-
obstructive plaque as judged at coronary angiography. The aims of this
study were: (1) to determine the relationship between this extent score and
traditional risk factors, as well aa more recently described predictors of CAD:
Lp(a) and dense LDL; and (2) todetarmine which risk factors were associated
with extensive rather than severe (obstructive) CAD.
Five hundred patients (349 men, age 61 + 11 years) who presented for
elective coronary angiogrsphy were assessed for (a) the extent end severity
of CAD and (b) the preaence of risk factors for CAD. Mean extent score was
55/100 (interquartile range 32-60). The presence of diabetes (p < 0.001),
currant or former smoking (p < 0005) and history of hypertension (p <
0.001) were associated with CAD extent. In the 321 patiente with a severity
score of Oor 1, diabetes wae associated with a greater extent (56% V 42%,
p < 0.005). In the 150 patients with detailed lipid data, extent of CAD was
correlated independently with age (p < 0.005), male gender (p < 0.05),
presence of diabetes (p < 0.05), Lp(a) (p < 0.005) and LDL/HDL ratio (p <
0.01).
Therefore, high CAD extent scores are associated with traditional CAD
risk factors and Lp(a) levels. In subjects with O or 1 vassel disease, the
presence of diabetes is associated with worse extent scores and potentially
higher risk of acute coronary events.
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m1059142 CoronaryStentinginWomen:Earlyin-Hoepitel
andLong-TermClinicalOutcomes
R. Mehran, T.A. Bucher, A.J. Lsnsky, J.J. Popma, G.S. Mintz, M.K. Hong,
J.R. Laird, L.F. Satler, K.M. Kent, A.D. Pichard, N.V. Summers, e. Wang,
M.B. Leon. Washington Hospital Centec Washington, DC, USA
Although women have higher reported peri-procedural complications and
worse outcomes compared to men during balloon angioplasty (NHLBI Reg-
istty), the impact of corona~ stanting on acute procedural resulta and long
term clinical outcome has not been studied. We analyzed the initial and long
term clinical outcome of 1200 patients (838 men vs 364 women) who had
parcutsneous revascularization of native coronaty lesions with stenting. Le-
sions were matched for reference vessel size, minimal lumen diameter, %
diameter stenosis by qualitative angiography, and cross sectional narrowing
(plaque/arterial area) by intravascular ultrasound.
Female Male P
In-HospitalComplications:
Q-wave Ml (%) 1.3 0.4 0.049
Non Q-wava Ml (%) 14.7 11,2 0.961
Death + Ml + CABG (4A) 3.7 2.2 0.135
VascularComplications(%) 9,4 3.9 <0.0001
Follow-up:(> 6 months)
Death (%) 1,1 0.78
Q-wave Ml (%)
0.49s
1.2 0.90 0.641
TLR (“A) 11.2 ta7 0.139
Any Event (%) 22.7 21.6 0.690
Weconc/ude: Despite stenting, women continue to have somewhat worse
in-hospital clinical complications when compared to men, perhaps seconda~
to other confounding factors (ie. oldar age, more diabetes, smaller body
surface area). However, at follow-up, the lower clinical event rates obsenred
after stents are similar in both groups.
1059-143 EetrogenReplacementTherapytieaucesRepeat
Revascularizstioni PostMenopausalWomen
afterIntracoronsryStenting:A LongTerm
FollowUP
D. Singh, M.W. Liu, A. Mathur, C. Piamsonboon, S.S. lyer, J.M. Patfe.,
R. Sutor, L.S. Dean, W.A. Baxley, G.S. Roubin. Division of Cardiovascuk?r
Diesease, The University of Alabama at Birmingham, Birmingham, AL, USA
Estrogan replacement therapy has been shown to reduce coronary morbidity
and mortality in post menopausal women. Between June 1993 and March
1996two groups of post menopausal women, one receivingestrogen therapy
(69 patienta), and the other no estrogen (60 patients) undarwent success-
ful intrscoronary stenting. Among the two groupa, 62 out of 69 and 55 out
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of 60 were followed up to August 1996 to evaluate the impact of estrogen
therapy on target lesion revaacularization. Eatrogen therapy was continued
throughout the follow-up (FU) period. Between the two groups, there was
no significant difference in age, incidence of coronaty risk factors (hyperten-
sion, diabetes mellitus, hypercholesterolemia and smoking), LVdysfunction,
incidence of multiveasel disease, lesion morphology, vessel site stented and
number of atents per vessel or types of stent (Cook vs. JJIS). The long-term
outcomes are as follows:
Estrogen (n= 62) No Estrogen (n =55) p Value
FU davs 556 & 2S4 516 + 267 ns
i+ci;;intengina 2 (3”/0) s (15%) 0.04
Revascularization 12 (19%) 24 (44°/0) 0.0065
(PTCA and CABG) Death O 1 ne
FU angiograms were obtained only in 26 out of 62 in estrogen treatment
group with angiographic restenosis of 50% and 26 out of 55 in no estrogen
treatment group with restenosis of 85%.
Conclusions: Estrogen replacement therapy in post menopausal women
reduces angina and target lesion revascularization after intrecoronary atent-
ing. Further substantiation by large randomized studies is needed.
m1059144 OptimalCoronaryStentinginDiabetice:A ViabiePercutanaouaAlternativeto CardiacSurgery
F.V.Tilli, D. Aliabadi, T. Bowera, ‘M.M. Shoukfeh, M. Spybrook, R.D. Sefian.
William Beaumont Hospital, Royal Oak, Ml, USA
Diabetics have significantly higher ratas of target vessel revascularization
(TVR) compared with non-diabetics following percutaneous intervention.
Earlier studies have reported TVR rates > 50% in diabetics despite use
of intracoronafy atents. Recent randomized studies have sugge6ted that
diabetics with multi-vassel coronaIy disease fare better with surgical revas-
txrlarization. In the era of optimal coronary stenting, however, it may be
possible to minimize the need for TVR in diabetics, thareby making percuta-
neous revascularization more attractive. We assessed 9 month TVR in 316
consecutive patients stented between 11/94and 6/95, 81 of whom were dia-
betic. All stents were implanted using routine high pressure post-dilatations.
Diabetes was a strong predictor of TVR, necessary in 24/61 (W%) diabetics
vs. 36/234 (15%) non-diabetics, (p= 0.008). Recurrentangina prompted TVR
in 57/60 (95%) of cases.
Conclusions: Diabetes increases the likelihood of need for TVR two-fold
compared with non-diabetics. Despite this, use of optimal stenting technique
can result in mora acceptable restenosis rates compared with early stent
experience in diabetics. Whether percutaneous revascularization employing
optimal stenting technique compares favorably with surgery for diabetics with
multi-vessel coronary disease requires further investigation.
m1059145 NoExcaaaMotteiityAfterCoronaryAngiopiaetyin Diabetic Patienta with Multiveaael Dieeaee
after Prior Bypaaa Surgery
E. Frantz, P. Pfautsch, S. Mr%ldel,E. Fleck. Cardiology, Virchow C/inic,
Humboldt University and German Hear?Institute, Berfin, Germany
Recently an alert has been issued, that patients (pts) on drug treatment for
diabetes mellitus with multivessel CAD should not be treated by PTCA be-
cause of increased mortality compared to corona~ bypass surgery (CABG).
We investigated, whether this also is relevant for pts with recurrent ischemia
after prior CABG surgery.
n = 489 pts. (46.6 + 44 months after CABG) were treated by PTCA
(n = 438) or”Re-CABG (n = 51). Diabetes was present in 99 pts (20.2%),
(18.9% in PTCA; 31.4% in Re-CABG-groupa, resp.). During follow-upof 32.0
+ 25.2 months, 44 pts. died (30 in PTCA-group, 14 in Re-CABG-group).
3-yr-Mortality was 37.4% in diabetic pts. in Re-CABG-group, 25.7% in non-
diabetics in Re-CABG-group, 7.2% in diabetics in PTCA-group and 7.4%
in non-diabetics in PTCA-group. Cox hazard analysis identified diabetes as
risk factor for death with x 1.43 rel. risk (p < 0.007) in all patients, Survival
Cuwes:
Conclusions: In this series, redo bypass surgery resulted in higher death
rates than angioplasty for diabetic patients as well as for non-diabetic pa-
tients. Nevertheless, irrespective of treatment ragimen, diabetes is a risk
factor for fatal adverse cardiac events at follow-up.
11059-1461 CoronaryStentingintheDiabeticPatients:~ariy
and Follow-up Reeulta
H. Yokoi, H. Noaake, T. Kimura, T. Tamura, Y. Nakagawa, N. Hamasaki,
M. Nobuyoshi. Kokura Memorial Hospital, Kitakyushu, Japap
Balloon PTCA in diabetic (D) patients (pts) has been associated with iess
favorable outcomes due to their increased incidence of restenosis and pro-
gression of disease. To assess whether Palmez-Schatz (PS) stent iaa useful
alternative to bailoon PTCA in D, immediate and follow-up (FU) results were
analyzed in consecutive 931 pts received PS implantation and compared D
pts with none-diabetic (ND) pts. Clinical success was defined as < 50% resid-
ual stenosis without death, CABG, Q-wave Ml. FU quantitative angiography
was obtained from 819 pts (66Y0)after 6 months or earlier when indicated
by symptoms. Clinical FU data was obtained after 12 months. Event-free
survival was definsd as free from death, Ml, CABG, target and new lesion
PTCA at FLL
D (N = 2s3) ND (N = 66s)
.,
Multi Vsseel*/Poor LV* (OA) 69/18 57/12
Calcification (%VLL (mm) 24/12,5 1S/11.8
Reference diam’eter(mmj 3,24 + 0.65 3.23 + 0.84
Pre MLD (mm) 0.76 + 0.46 0.76 + 0.47
Post MLD (mm) 2.66 + 0.50 2.88 + 0.49
Clinical Success (%) 97 95
Death/Ml/CABG (%) 0.4/1 .1/0.4 2.3/1 .5/1.2
Thromboeia (%) 0.s 1,s
Bleeding complication (%) 4.6 4.9
FU MLD* (mm) 1.93 * 0.91 2.06 l 0.82
Binaiy restenosis*~LR (%) 29/19 22/15
Event Free Suivivsl (%) 32 27
*p <0.05, MLD = minimal lumen diameter, LL = iesion length
Conclusion: 1) PS stent implantation can be performed in D pts with the
acceptable complications despite unfavorable clinical environment. 2) But
restenosis following stenting in D is significantly higher because of greater
late loss, probably reflecting more aggressive intimal hyperplasia.
I1059-147I Corona~stentingDUringEmergency
Angioplasty in High-Risk Myocardial Infarction:
Data From a Multicenter Registry
G.Steffenino 1,S. Chierchia, A. Fontaneili, L. Niccoli, S. Repetto, G. Risice
for the RAI Regisby Investigators. ‘ Di!z of Cardiology Ospeda/e S. Croce,
Cuneoj /fa/y
Use of coronary atents (CS) during amergency angioplasty (EM-PTCA) in
acute myocardial infarction (AMI) is controversial. The l-year RAi registry
was started in November ’95 to monitor the pariormance, in-hospital and
6-month outcome, and resource use of EM-PTCA in high-risk AMI (large
anterior or inferior, recurrent, post CABG, with pump failure), in 6 Centers
where EM-PTCA is currently performed. In the Ist semester PTCA was
attempted in 135 pts, with use of CS in 68 pts (50%): 6 women, age 56 +
10 (29-79 y). Five pts had failed iv Iysis, and 9 (13%) were in shock. CS
were implanted immediately after PTCA in all cases: the indication was a
threatening dissection or unsatisfactory balioon result in 55 pts, and elective
in 13 (19%). Vessel distribution was as follows: 36 LAD (53%), 23 RCA, 4
Cx/OM, and 5 SVG. IABP was used in 15 pts (22%) Immediate success was
achieved in 67 pts (99%), with balloons of 3.4 + 0.3 mm at 15 + 2 atm.
Multipie CS were uaed in 14 pts. (21%). Final flow was TIMI 3 and 2 in 65
and 3 ceees, respectively,and residual StenOSiSwas 12 + 4%.; pain was
absent in 60 pts, with a normal ST segment in 32 (47%). During hospitai stay
(10 + 4 d; 5-24) 6 pts (9%) had subacute CS occlusion (with redo PTCA in
3, and CABG in 2), 2 pts had vascular repair, and 5 pts (7Yo)died, due to
persistent shock in 3. Medication at discharge (61 pts) inciuded ticlopidine
alone in 40 pta (66Yo),aspirin alone in 7 pts, both in 8 pts, and antimagulants
in 6 pts. Follow-up angiographic results in this cohort will be available in Nov.
’96. /n conclusion.’CS may increase the immediate success of EM-PTCA in
the compromised pt with high-risk AMI, with few complications.
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